Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-08-14

Actuate Therapeutics (ACTU)

CEO Daniel Schmitt was paid $2,166,522 in fiscal year 2025, ↓ down 61.2% from fiscal year 2024 (SEC filing 0001683168-26-002691 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$2,166,522 ↓
Daniel Schmitt total, FY2025
—
CEO pay percentile vs peers
—
CEO-to-median pay ratio
—
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

ACTU's next annual pay disclosure, estimated April 4, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Daniel Schmitt$570,000$142,329$0$1,454,193$0$0$0$2,166,522
President and Chief Executive Officer
Andrew Mazar450,000102,1500867,4190001,419,569
Chief Operating Officer
Paul Lytle435,36379,0620491,9360001,006,361
Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Daniel Schmitt$2,166,522$5,578,616—↓ −3,412,094
Andrew Mazar1,419,569675,000—↑ +744,569
Paul Lytle1,006,3611,896,096—↓ −889,735

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Actuate Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ACTU reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against ACTU
1 company names ACTU as a compensation peer

The list of companies that name ACTU as a peer is temporarily unavailable — recheck shortly.

01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Aaron G.L. FletcherChair of the Board$181,995
Amy RonnebergIndependent Director$159,495
Dan ZabrowskiIndependent Director$159,995
Jason KeyesIndependent Director$162,995
Roger SawhneyIndependent Director$159,495
Todd ThomsonIndependent Director$147,995
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Amy RonnebergDirector2026-05-21A15,000$0$0Derivative, Class A CommonForm 4 ↗
Todd ThomsonDirector2026-05-21A15,00000Derivative, Class A CommonForm 4 ↗
Aaron G.L. FletcherDirector2026-05-21A15,00000Derivative, Class A CommonForm 4 ↗
Martin H. Huber Jr.Director2026-05-21A15,00000Derivative, Class A CommonForm 4 ↗
Jason KeyesDirector2026-05-21A15,00000Derivative, Class A CommonForm 4 ↗
Roger SawhneyDirector2026-05-21A15,00000Derivative, Class A CommonForm 4 ↗
Dan ZabrowskiDirector2026-05-21A15,00000Derivative, Class A CommonForm 4 ↗
Daniel M. SchmittDirector2026-08-14D120,5211121,726CommonForm 4 ↗
Daniel M. SchmittDirector2026-08-14D272,05600Derivative, Class A CommonForm 4 ↗
Daniel M. SchmittDirector2026-08-14A272,05600CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Andrew MazarOption—————$867,419
Paul LytleOption—————491,936
Daniel SchmittOption—————1,454,193
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Andrew Mazar$0$0$867,4190.0%
Paul Lytle00491,9360.0%
Daniel Schmitt001,454,1930.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Andrew MazarRSU5,891—$36,053
Daniel SchmittOption66,5036.7—
Paul LytleOption234,9718—
Andrew MazarOption37,3742.14—
Daniel SchmittRSU272,056—1,664,983
Andrew MazarOption110,3466.7—
Daniel SchmittPSU5,891—36,053
Paul LytleOption41,8996.7—
Daniel SchmittPSU272,056—1,664,983
Daniel SchmittOption136,1916.7—
Andrew MazarOption51,0466.7—
Daniel SchmittOption204,2856.7—
Andrew MazarOption17,1302.14—
Paul LytleOption146,8578—
Paul LytleOption27,9336.7—
Paul LytleOption49,3946.7—
Andrew MazarOption73,5646.7—
Daniel SchmittRSU11,726—71,763
05

Incentive-plan design — the Compensation Discussion & Analysis

For the years ended December 31, 2025 and 2024, the compensation program for our named executive officers consisted of base salary and incentive compensation delivered in the form of cash bonuses and equity awards. Base salary was set at a level that was commensurate with the executive's duties and authorities, contributions, prior experience and sustained performance.

CEO STI target (% of salary)55%
CEO LTI target (% of salary)—
Independent consultantAnderson Pay Advisors LLC
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
07

CEO pay ratio

Ratio (CEO : median employee)—
CEO total compensation—
Median employee compensation—
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Aaron G.L. FletcherIndependent · Board Chair · Nominating/Governance (Chair)$78,000$0$103,995—$0$181,995
Jason KeyesIndependent · Audit (Chair)59,0000103,995—0162,995
Dan ZabrowskiIndependent · Compensation (Chair) · Nominating/Governance56,0000103,995—0159,995
Roger SawhneyIndependent · Audit · Compensation55,5000103,995—0159,495
Amy RonnebergIndependent · Audit · Compensation55,5000103,995—0159,495
Todd ThomsonIndependent · Nominating/Governance44,0000103,995—0147,995
Daniel M. SchmittEmployee director000—00
09

Board fee structure and ownership guideline

Annual cash retainer—
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)—
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$348,000
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$348,000

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Actuate Therapeutics2025Daniel Schmitt$570,000$0$1,454,193$0$2,166,522

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Actuate Therapeutics in fiscal 2025?
As disclosed, Daniel Schmitt (President and Chief Executive Officer) was the highest-paid executive at Actuate Therapeutics in fiscal 2025, with total compensation of $2,166,522.
How much does Actuate Therapeutics spend in total on board compensation for fiscal 2025?
As disclosed, Actuate Therapeutics reported total board compensation of $348,000 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Daniel SchmittDEF 14A2026-04-060001683168-26-002691Section “Summary Compensation Table”. As printed: 2,166,522. Filing ↗machine: r1 · c19 · span 185828–185837
2Section 01, Andrew MazarDEF 14A2026-04-060001683168-26-002691Section “Summary Compensation Table”. As printed: 1,419,569. Filing ↗machine: t53 · r3 · c19 · span 187598–187607
3Section 01, Paul LytleDEF 14A2026-04-060001683168-26-002691Section “Summary Compensation Table”. As printed: 1,006,361. Filing ↗machine: r5 · c19 · span 189249–189258
4Section 03, Andrew Mazar OptionDEF 14A2026-04-060001683168-26-002691Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t53 · r3 · c13 · span 187394–187401
5Section 03, Paul Lytle OptionDEF 14A2026-04-060001683168-26-002691Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t53 · r5 · c13 · span 189045–189052
6Section 03, Daniel Schmitt OptionDEF 14A2026-04-060001683168-26-002691Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t53 · r1 · c13 · span 185542–185551
7Section 07, pay ratioDEF 14A2026-04-060001683168-26-002691Section “CEO Pay Ratio”. As printed: —. Filing ↗
8Section 08, Aaron G.L. FletcherDEF 14A2026-04-060001683168-26-002691Section “Director Compensation”. As printed: 181,995. Filing ↗machine: t62 · r1 · c15 · span 251777–251784
9Section 08, Jason KeyesDEF 14A2026-04-060001683168-26-002691Section “Director Compensation”. As printed: 162,995. Filing ↗machine: t62 · r2 · c15 · span 252484–252491
10Section 08, Dan ZabrowskiDEF 14A2026-04-060001683168-26-002691Section “Director Compensation”. As printed: 159,995. Filing ↗machine: t62 · r6 · c15 · span 255307–255314
11Section 08, Roger SawhneyDEF 14A2026-04-060001683168-26-002691Section “Director Compensation”. As printed: 159,495. Filing ↗machine: t62 · r4 · c15 · span 253894–253901
12Section 08, Amy RonnebergDEF 14A2026-04-060001683168-26-002691Section “Director Compensation”. As printed: 159,495. Filing ↗machine: t62 · r3 · c15 · span 253190–253197
13Section 08, Todd ThomsonDEF 14A2026-04-060001683168-26-002691Section “Director Compensation”. As printed: 147,995. Filing ↗machine: t62 · r5 · c15 · span 254602–254609
14Section 08, Daniel M. SchmittDEF 14A2026-04-060001683168-26-002691Section “Director Compensation”. As printed: 0. Filing ↗
15Section 02, Amy Ronneberg 2026-05-21Form 42026-05-220001683168-26-004251Insider equity transaction reported since the proxy statement. Filing ↗
16Section 02, Todd Thomson 2026-05-21Form 42026-05-220001683168-26-004257Insider equity transaction reported since the proxy statement. Filing ↗
17Section 02, Aaron G.L. Fletcher 2026-05-21Form 42026-05-220001683168-26-004241Insider equity transaction reported since the proxy statement. Filing ↗
18Section 02, Martin H. Huber Jr. 2026-05-21Form 42026-05-220001683168-26-004243Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Jason Keyes 2026-05-21Form 42026-05-220001683168-26-004245Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Roger Sawhney 2026-05-21Form 42026-05-220001683168-26-004255Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Dan Zabrowski 2026-05-21Form 42026-05-220001683168-26-004260Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Daniel M. Schmitt 2026-08-14Form 42026-08-140001683168-26-006493Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Daniel M. Schmitt 2026-08-14Form 42026-08-140001683168-26-006493Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Daniel M. Schmitt 2026-08-14Form 42026-08-140001683168-26-006493Insider equity transaction reported since the proxy statement. Filing ↗
25Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
26Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
27Section 09b board cost (computed)Computed——Cash 348,000 + equity 0 + all other 0 = 348,000, summed across the director compensation table rows.machine: formula: Σ = 348,000
28Actuate Therapeutics (subject), Section 10b CEO totalDEF 14A2026-04-060001683168-26-002691CEO total compensation as printed in Actuate Therapeutics's own proxy. As printed: 2,166,522. Filing ↗machine: r1 · c19 · span 185828–185837

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.